Great Point Partners (GPP) has acquired Lyocontract GmbH (Lyocontract), a premium independent drug product contract development and manufacturing organization (CDMO) based in Ilsenburg, Germany.

Founded in 2007, Lyocontract operates from a state-of-the-art pharmaceutical manufacturing facility providing aseptic liquid filling, lyophilization, and packaging services. Compliant with the European Union’s Annex 1 standards, the Company specializes in the production of liquid and freeze-dried parenteral drugs, distributing globally for both clinical and commercial use.

The acquisition marks the first investment to be sourced and executed by GPP’s European team, which is based in the firm’s recently opened London office. Consistent with GPP’s core strategic focus, GPP’s European team aims to help growing health care companies become global and enter the US market.

“Lyocontract has an opportunity to further scale and broaden its offerings and expand its global capabilities at a time when there is growing demand for lyophilization services,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP.

“We look forward to leveraging our experience strengthening successful CDMOs to solidify Lyocontract’s position as a global industry leader,” Rhodes added.

“Lyocontract has a strong track record of providing highly specialized and critically important manufacturing services to pharmaceutical companies, bringing a powerful combination of experience, expertise and technological capabilities to all of its partnerships,” said David Slattery, Senior Vice President at GPP.

“This investment underscores GPP’s dedication to backing exceptional, proven management teams in businesses with a competitive advantage,” Slattery added.

“GPP’s capital resources, paired with the firm’s strategic and tactical counsel, will be invaluable in helping us further scale Lyocontract’s contract manufacturing capabilities and distribution reach,” said Dr. Tino Galgon, CEO of Lyocontract.

“We look forward to our next chapter as we embark on an exciting phase of growth to deliver products of the highest quality,” Dr. Tino Galgon added.